A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Trial Profile

A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Sargramostim (Primary) ; Florbetapir F 18
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 1 Apr 2018 to 31 Mar 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 31 Mar 2017.
    • 05 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment due to slow recruitment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top